Literature DB >> 18725441

In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.

R Fernández-Roblas1, N Z Martín-de-Hijas, A I Fernández-Martínez, D García-Almeida, I Gadea, J Esteban.   

Abstract

We evaluated the in vitro activities of tigecycline and 10 other antibiotics against clinical isolates of nonpigmented rapidly growing mycobacteria. Fifteen collection strains and 165 clinical isolates were included in the study. Tigecycline showed the highest activity among all antibiotics studied: all the strains were inhibited by 1 mg/liter.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18725441      PMCID： PMC2573152          DOI： 10.1128/AAC.00695-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 2.  Tigecycline.

Authors:  George A Pankey
Journal:  J Antimicrob Chemother       Date:  2005-07-22       Impact factor: 5.790

3.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.

Authors:  A Telenti; F Marchesi; M Balz; F Bally; E C Böttger; T Bodmer
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

4.  Activities of linezolid against rapidly growing mycobacteria.

Authors:  R J Wallace; B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey.

Authors:  N Martín-Casabona; A R Bahrmand; J Bennedsen; V Ostergaard Thomsen; M Curcio; M Fauville-Dufaux; K Feldman; M Havelkova; M L Katila; K Köksalan; M F Pereira; F Rodrigues; G E Pfyffer; F Portaels; J Rosselló Urgell; S Rüsch-Gerdes; E Tortoli; V Vincent; B Watt
Journal:  Int J Tuberc Lung Dis       Date:  2004-10       Impact factor: 2.373

6.  In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials.

Authors:  R Fernández-Roblas; J Esteban; F Cabria; J C López; M S Jiménez; F Soriano
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

7.  Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Epidemiology of infections due to nonpigmented rapidly growing mycobacteria diagnosed in an urban area.

Authors:  J Esteban; N Z Martín-de-Hijas; A-I Fernandez; R Fernandez-Roblas; I Gadea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-05-06       Impact factor: 3.267

Review 9.  Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

10.  Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.

Authors:  B A Brown; R J Wallace; G O Onyi; V De Rosas; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191
View more
  11 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  Prosthetic joint infection caused by Mycobacterium alvei in an elderly patient.

Authors:  Chen-Hsiang Lee; Huey-Ling You; Jun-Wen Wang; Ya-Fen Tang; Jien-Wei Liu
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

3.  In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

4.  Drug susceptibility patterns of rapidly growing mycobacteria isolated from skin and soft tissue infections in Venezuela.

Authors:  Omaira Da Mata-Jardín; Alejandro Angulo; Margarita Rodríguez; Sandra Fernández-Figueiras; Jacobus H de Waard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-18       Impact factor: 3.267

5.  In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents.

Authors:  Hui Pang; Guilian Li; Li Wan; Yi Jiang; Haican Liu; Xiuqin Zhao; Zhongfu Zhao; Kanglin Wan
Journal:  Int J Clin Exp Med       Date:  2015-09-15

6.  Mycobacterium abscessus drug discovery using machine learning.

Authors:  Alan A Schmalstig; Kimberley M Zorn; Sebastian Murcia; Andrew Robinson; Svetlana Savina; Elena Komarova; Vadim Makarov; Miriam Braunstein; Sean Ekins
Journal:  Tuberculosis (Edinb)       Date:  2022-01-20       Impact factor: 3.131

7.  In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2022-08-09       Impact factor: 5.938

8.  In vitro activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia species.

Authors:  Michael Cynamon; Jeff Jureller; Balaji Desai; Krithika Ramachandran; Mary Sklaney; Trudy H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

Review 9.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577

10.  Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue assay.

Authors:  Guilian Li; Lu-Lu Lian; Li Wan; Jingrui Zhang; Xiuqin Zhao; Yi Jiang; Li-Li Zhao; Haican Liu; Kanglin Wan
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.